|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Itaya T, Yamaoto N, Ando M, Ebisawa M,
Nakamura Y, Murakami H, Asai G, Endo M and Takahashi T: Influence
of histological type, smoking history and chemotherapy on survival
after first-line therapy in patients with advanced non-small cell
lung cancer. Cancer Sci. 98:226–230. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Yang M, Shen H, Qiu C, Ni Y, Wang L, Dong
W, Liao Y and Du J: High expression of miR-21 and miR-155 predicts
recurrence and unfavourable survival in non-small cell lung cancer.
Eur J Cancer. 49:604–615. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Sun S, Schiller JH, Spinola M and Minna
JD: New molecularly targeted therapies for lung cancer. J Clin
Invest. 117:2740–2750. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zarogoulidis P, Darwiche K, Sakkas A,
Yarmus L, Huang H, Li Q, Freitag L, Zarogoulidis K and Malecki M:
Suicide gene therapy for cancer-current strategies. J Genet Syndr
Gene Ther. 4:168492013.PubMed/NCBI
|
|
6
|
Lv SQ, Zhang KB, Zhang EE, Gao FY, Yin CL,
Huang CJ, He JQ and Yang H: Antitumor efficiency of the cytosine
deaminase/5-fluorocytosine suicide gene therapy system on malignant
gliomas: an in vivo study. Med Sci Monit. 15:BR13–BR20.
2009.PubMed/NCBI
|
|
7
|
Finocchiaro LM, Riveros MD and Glikin GC:
Cytokine-enhanced vaccine and suicide gene therapy as adjuvant
treatments of metastatic melanoma in a horse. Vet Rec. 164:278–279.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ju DW, Yang Y, Tao Q, Song WG, He L, Chen
G, Gu S, Ting CC and Cao X: Interleukin-18 gene transfer increases
antitumor effects of suicide gene therapy through efficient
induction of antitumor immunity. Gene Ther. 7:1672–1679. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Drozdzik M, Qian C, Xie X, Peng D, Bilbao
R, Mazzolini G and Prieto J: Combined gene therapy with suicide
gene and interleukin-12 is more efficient than therapy with one
gene alone in a murine model of hepatocellular carcinoma. J
Hepatol. 32:279–286. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Warren P, Song W, Holle E, Holmes L, Wei
Y, Li J, Wagner T and Yu X: Combined HSV-TK/GCV and secondary
lymphoid tissue chemokine gene therapy inhibits tumor growth and
elicits potent antitumor CTL response in tumor-bearing mice.
Anticancer Res. 22:599–604. 2002.PubMed/NCBI
|
|
11
|
Kerkar SP, Muranski P, Kaiser A, Boni A,
Sanchez-Perez L, Yu Z, Palmer DC, Reger RN, Borman ZA, Zhang L, et
al: Tumor-specific CD8+ T cells expressing
interleukin-12 eradicate established cancers in lymphodepleted
hosts. Cancer Res. 70:6725–6234. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Terao S, Shirakawa T, Goda K, Kamidono S,
Fujisawa M and Gotoh A: Recombinant interleukin-2 enhanced the
antitumor effect of ADV/RSV-HSV-tk/ACV therapy in a murine bladder
cancer model. Anticancer Res. 25:2757–2760. 2005.PubMed/NCBI
|
|
13
|
Hall SJ, Canfield SE, Yan Y, Hassen W,
Selleck WA and Chen SH: A novel bystander effect involving tumor
cell-derived Fas and FasL interactions following Ad.HSV-tk and
Ad.mIL12 gene therapies in experimental prostate cancer. Gene Ther.
9:511–517. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Nasu Y, Bangma CH, Hull GW, Yang G, Wang
J, Shimura S, McCurdy MA, Ebara S, Lee HM, Timme TL and Thompson
TC: Combination gene therapy with adenoviral vector-mediated
HSV-tk+GCV and IL-12 in an orthotopic mouse model for prostate
cancer. Prostate Cancer Prostatic Dis. 4:44–55. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Fogar P, Greco E, Basso D, Habeler W,
Navaglia F, Zambon CF, Tormen D, Gallo N, Cecchetto A, Plebani M
and Pedrazzoli S: Suicide gene therapy with HSV-TK in pancreatic
cancer has no effect in vivo in a mouse model. Eur J Surg Oncol.
29:721–730. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Okada Y, Okada N, Mizuguchi H, Hayakawa T,
Nakagawa S and Mayumi T: Transcriptional targeting of RGD
fiber-mutant adenovirus vectors can improve the safety of suicide
gene therapy for murine melanoma. Cancer Gene Ther. 12:608–616.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Schoensiegel F, Paschen A, Sieger S,
Eskerski H, Mier W, Rothfels H, Kleinschmidt J, Schadendorf D and
Haberkorn U: MIA (melanoma inhibitory activity) promoter mediated
tissue-specific suicide gene therapy of malignant melanoma. Cancer
Gene Ther. 11:408–418. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Curvelo JA, Barreto AL, Portela MB,
Alviano DS, Holandino C, Souto-Padrón T and Soares RM: Effect of
the secretory leucocyte proteinase inhibitor (SLPI) on Candida
albicans biologicalprocesses: A therapeutic alternative? Arch
Oral Biol. 59:928–937. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ameshima S, Ishizaki T, Demura Y, Imamura
Y, Miyamori I and Mitsuhashi H: Increased secretory leukoprotease
inhibitor in patients with non-small cell lung carcinoma. Cancer.
89:1448–1456. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zuo J, Zhang C, Ren C, Pang D, Li Y, Xie
X, Tang Z and Jiang X: Secretory leukocyte protease inhibitor is a
proliferation and survival factor for pancreatic cancer cells. Clin
Transl Oncol. 17:314–321. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Hough CD, Cho KR, Zonderman AB, Schwartz
DR and Morin PJ: Coordinately up-regulated genes in ovarian cancer.
Cancer Res. 61:3869–3876. 2001.PubMed/NCBI
|
|
22
|
Franken C, Meijer CJ and Dijkman JH:
Tissue distribution of antileukoprotease and lysozyme in humans. J
Histochem Cytochem. 37:493–498. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Chen PJ, Kuo MY, Chen ML, Tu SJ, Chiu MN,
Wu HL, Hsu HC and Chen DS: Continuous expression and replication of
the hepatitis delta virus genome in Hep G2 hepatoblastoma cells
transfected with cloned viral DNA. Proc Natl Acad Sci USA.
87:5253–5257. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Alexandrova R: Experimental strategies in
gene therapy of cancer. J Buon. 14:S23–S32. 2009.PubMed/NCBI
|
|
25
|
Fukazawa T, Matsuoka J, Yamatsuji T, Maeda
Y, Durbin ML and Naomoto Y: Adenovirus-mediated cancer gene therapy
and virotherapy (Review). Int J Mol Med. 25:3–10. 2010.PubMed/NCBI
|
|
26
|
Das SK, Menezes ME, Bhatia S, Wang XY,
Emdad L, Sarkar D and Fisher PB: Gene therapies for cancer:
Strategies, challenges and successes. J Cell Physiol. 230:259–271.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Nettelbeck DM, Jérôme V and Müller R: Gene
therapy: Designer promoters for tumour targeting. Trends Genet.
16:174–181. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Luo XR, Li JS, Niu Y and Miao L: Targeted
killing effects of double CD and TK suicide genes controlled by
survivin promoter on gastric cancer cell. Mol Biol Rep.
38:1201–1207. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Teimoori-Toolabi L, Azadmanesh K,
Amanzadeh A and Zeinali S: Selective suicide gene therapy of colon
cancer exploiting the urokinase plasminogen activator receptor
promoter. BioDrugs. 24:131–146. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Nakamura K, Takamoto N, Hongo A, Kodama J,
Abrzua F, Nasu Y, Kumon H and Hiramatsu Y: Secretory leukoprotease
inhibitor inhibits cell growth through apoptotic pathway on ovarian
cancer. Oncol Rep. 19:1085–1091. 2008.PubMed/NCBI
|
|
31
|
Tsukishiro S, Suzumori N, Nishikawa H,
Arakawa A and Suzumori K: Use of serum secretory leukocyte protease
inhibitor levels in patients to improve specificity of ovarian
cancer diagnosis. Gynecol Oncol. 96:516–519. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Robertson MW III, Wang M, Siegal GP,
Rosenfeld M, Ashford RS II, Alvarez RD, Garver RI and Curiel DT:
Use of a tissue-specific promoter for targeted expression of the
herpes simplex virus thymidine kinase gene in cervical carcinoma
cells. Cancer Gene Ther. 5:331–336. 1998.PubMed/NCBI
|
|
33
|
Barker SD, Coolidge CJ, Kanerva A,
Hakkarainen T, Yamamoto M, Liu B, Rivera AA, Bhoola SM, Barnes MN,
Alvarez RD, et al: The secretory leukoprotease inhibitor (SLPI)
promoter for ovarian cancer gene therapy. J Gene Med. 5:300–310.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Maemondo M, Saijo Y, Narumi K, Kikuchi T,
Usui K, Tazawa R, Matsumoto K, Nakamura T, Sasaki K, Takahashi M,
et al: Gene therapy with secretory leukoprotease inhibitor
promoter-controlled replication-competent adenovirus for non-small
cell lung cancer. Cancer Res. 64:4611–4620. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Uchibori R, Okada T, Ito T, Urabe M,
Mizukami H, Kume A and Ozawa K: Retroviral vector-producting
mesenchymal stem cells for targeted suicide cancer gene therapy. J
Gene Med. 11:373–381. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Nanni P, Rossil L, De Giovanni C, Landuzzi
L, Nicoletti G, Stoppacciaro A, Parenza M, Colombo MP and Lollini
PL: Interleukin 12 gene therapy of MHC-negative murine melanoma
metastases. Cancer Res. 58:1225–1230. 1998.PubMed/NCBI
|
|
37
|
Loskog A, Björkland A, Brown MP, Korsgren
O, Malmström PU and Tötterman TH: Potent antitumor effects of CD154
transduced tumor cells in experimental bladder cancer. J Urol.
166:1093–1097. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Brand K, Arnold W, Bartels T, Lieber A,
Kay MA, Strauss M and Dörken B: Liver-associated toxicity of the
HSV-tk/GCV approach and adenoviral vectors. Cancer Gene Ther.
4:9–16. 1997.PubMed/NCBI
|
|
39
|
van der Eb MM, Cramer SJ, Vergouwe Y,
Schagen FH, van Krieken JH, van der Eb AJ, Rinkes Borel IH, van de
Velde CJ and Hoeben RC: Severe hepatic dysfunction after
adenovirus-mediated transfer of the herpes simplex virusthymidine
kinase gene and ganciclovir administration. Gene Ther. 5:451–458.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Larocca C and Schlom J: Viral vector-based
therapeutic cancer vaccines. Cancer J. 17:359–371. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Sterman DH, Recio A, Haas AR, Vachani A,
Katz SI, Gillespie CT, Cheng G, Sun J, Moon E, Pereira L, et al: A
phase I trial of repeated intrapleural adenoviral-mediated
interferon-beta gene transfer for mesothelioma and metastatic
pleural effusions. Mol Ther. 18:852–860. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Ring C, Harris JD, Hurst HC and Lemoine
NR: Suicide gene expression induced in tumor cells transduced with
recombinant adenoviral, retroviral and plasmid vectors containing
the promoter. Gene Ther. 3:1094–1103. 1996.PubMed/NCBI
|
|
43
|
Ejeskär K, Fransson S, Zaibak F and
Ioannou PA: Method for efficient transfection of in
vitro-transcribed mRNA into SK-N-AS and HEK293 cells: Difference in
the toxicity of nuclear EGFP compared to cytoplasmic EGFP. Int J
Mol Med. 17:1011–1016. 2006.PubMed/NCBI
|
|
44
|
Kamaci N, Emnacar T, Karakas N, Arikan G,
Tsutsui K and Isik S: Selective silencing of DNA topoisomerase IIβ
in human mesenchymal stem cells by siRNAs (small interfering RNAs).
Cell Biol Int Rep (2010). 18:e000102011.PubMed/NCBI
|
|
45
|
Dalby B, Cates S, Harris A, Ohki EC,
Tilkins ML, Price PJ and Ciccarone VC: Advanced transfection with
Lipofectamine 2000 reagent: Primary neurons, siRNA, and
high-throughput applications. Methods. 33:95–103. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Moolten FL: Tumor chemosensitivity
conferred by inserted herpes thymidine kinase genes: Paradigm for a
prospective cancer control strategy. Cancer Res. 46:5276–2581.
1986.PubMed/NCBI
|
|
47
|
Ambade AV, Joshi GV and Mulherkar R:
Effect of suicide gene therapy in combination with immunotherapy on
antitumour immuneresponse & tumour regression in a xenograft
mouse model for head & neck squamous cellcarcinoma. Indian J
Med Res. 132:415–422. 2010.PubMed/NCBI
|
|
48
|
Rodriguez SS, Castro MG, Brown OA, Goya RG
and Console GM: Gene therapy for the treatment of pituitary tumors.
Expert Rev Endocrinol Metab. 4:359–370. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Ramesh R, Marrogi AJ, Munshi A, Abboud CN
and Freeman SM: In vivo analysis of the ‘bystander effect’: A
cytokine cascade. Exp Hamatol. 24:829–838. 1996.
|
|
50
|
Wei MX, Bougnoux P, Sacré-Salem B, Peyrat
MB, Lhuillery C, Salzmann JL and Klatzmann D: Suicide gene therapy
of chemically induced mammary tumor in rat: Efficacy and distant
bystander effect. Cancer Res. 58:3529–3532. 1998.PubMed/NCBI
|
|
51
|
Kianmanesh AR, Perrin H, Panis Y, Fabre M,
Nagy HJ, Houssin D and Klatzmann D: A ‘distant’ bystander effect of
suicide gene therapy: Regression of nontransduced tumors together
with a distant transduced tumor. Hum Gene Ther. 8:1807–1814. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
52
|
van Dillen IJ, Mulder NH, Vaalburg W, de
Vries EF and Hospers GA: Influence of the bystander effect on
HSV-tk/GCV gene therapy. A review. Curr Gene Ther. 2:307–322. 2002.
View Article : Google Scholar : PubMed/NCBI
|
